Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate,… Read more
Egetis Therapeutics AB (publ) (EGTX) - Total Assets
Latest total assets as of June 2025: Skr654.40 Million SEK
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) holds total assets worth Skr654.40 Million SEK as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Egetis Therapeutics AB (publ) - Total Assets Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Egetis Therapeutics AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Egetis Therapeutics AB (publ)'s total assets of Skr654.40 Million consist of 48.0% current assets and 52.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 44.3% |
| Accounts Receivable | Skr23.60 Million | 3.0% |
| Inventory | Skr1.00 Million | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr408.00 Million | 51.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Egetis Therapeutics AB (publ)'s current assets represent 48.0% of total assets in 2024, an increase from 15.3% in 2008.
- Cash Position: Cash and equivalents constituted 44.3% of total assets in 2024, up from 13.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 51.5% of total assets.
Egetis Therapeutics AB (publ) Competitors by Total Assets
Key competitors of Egetis Therapeutics AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Egetis Therapeutics AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Egetis Therapeutics AB (publ) generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Egetis Therapeutics AB (publ) is currently not profitable relative to its asset base.
Egetis Therapeutics AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.56 | 7.29 |
| Quick Ratio | 1.08 | 1.55 | 7.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr19.70 Million | Skr 83.20 Million | Skr 141.44 Million |
Egetis Therapeutics AB (publ) - Advanced Valuation Insights
This section examines the relationship between Egetis Therapeutics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.84 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | Skr792.30 Million |
| Market Capitalization | $101.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Egetis Therapeutics AB (publ)'s assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Egetis Therapeutics AB (publ)'s assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Egetis Therapeutics AB (publ) (2008–2024)
The table below shows the annual total assets of Egetis Therapeutics AB (publ) from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr792.30 Million | +4.22% |
| 2023-12-31 | Skr760.20 Million | +35.48% |
| 2022-12-31 | Skr561.10 Million | -1.43% |
| 2021-12-31 | Skr569.27 Million | -36.32% |
| 2020-12-31 | Skr893.97 Million | +231.01% |
| 2019-12-31 | Skr270.07 Million | +11.58% |
| 2018-12-31 | Skr242.04 Million | -23.25% |
| 2017-12-31 | Skr315.37 Million | -20.45% |
| 2016-12-31 | Skr396.44 Million | +657.12% |
| 2015-12-31 | Skr52.36 Million | -49.39% |
| 2014-12-31 | Skr103.47 Million | +102.83% |
| 2013-12-31 | Skr51.01 Million | -15.62% |
| 2012-12-31 | Skr60.46 Million | -33.87% |
| 2011-12-31 | Skr91.42 Million | +976.56% |
| 2010-12-31 | Skr8.49 Million | +43.58% |
| 2009-12-31 | Skr5.91 Million | +10.12% |
| 2008-12-31 | Skr5.37 Million | -- |